Skip to content

Study · Measured the body's own peptide · 2020

1 result

Top-Down Proteomics of Human Saliva Discloses Significant Variations of the Protein Profile in Patients with Mastocytosis.

Serrao S, Firinu D, Olianas A, Deidda M, Contini C, Iavarone F, Sanna MT, Boroumand M, Amado F, Castagnola M, Messana I, Del Giacco S, Manconi B, Cabras T

Journal of proteome research6 Jul 2020Cited by 15 (Europe PMC)

PMID32575983 (opens in a new tab)PMCIDPMC8008451 (opens in a new tab)DOI10.1021/acs.jproteome.0c00207 (opens in a new tab)PepBankPUB-32575983
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

Mastocytosis is a myeloproliferative neoplasm causing abnormal clonal mast cell accumulation in different tissues, such as skin and bone marrow. A cutaneous subtype (CM) is distinguished from a systemic one (SM); SM patients can be grouped into SM with (SM+C) or without (SM-C) additional cutaneous lesions, and their classification is often challenging. This study was purposed to highlight variations in the salivary proteome of patients with different mastocytosis subtypes and compared to healthy controls. A top-down proteomics approach coupled to a label-free quantitation revealed salivary profiles in patients different from those of controls and a down-regulation of peptides/proteins involved in the mouth homeostasis and defense, such as statherin, histatins, and acidic proline-rich proteins (aPRPs), and in innate immunity and inflammation, such as the cathepsin inhibitors, suggesting a systemic condition associated with an exacerbated inflammatory state. The up-regulation of antileukoproteinase and S100A8 suggested a protective role against the disease status. The two SM forms were distinguished by the lower levels of truncated forms of aPRPs, statherin, P-B peptide, and cystatin D and the higher levels of thymosin β4 and α-defensins 1 and 4 in SM-C patients with respect to SM+C. Data are available via ProteomeXchange with identifier PXD017759.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In patients with systemic mastocytosis, salivary thymosin β4 levels were higher in those without cutaneous lesions (SM-C) than in those with them (SM+C).

    In plain wordsIn people with systemic mastocytosis, the body's own thymosin β4 in saliva was higher without skin lesions than with them.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseSalivary Tβ4 level, SM-C versus SM+C
    Study

    n: not reported in source

    Comparator
    SM+C patients
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    the higher levels of thymosin β4 and α-defensins 1 and 4 in SM-C patients with respect to SM+C.
    1 context sentence
    Summary · context
    This study was purposed to highlight variations in the salivary proteome of patients with different mastocytosis subtypes and compared to healthy controls.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.